Groven, Nina, Fors, Egil Andreas, Stunes, Astrid Kamilla et al. · Brain, behavior, & immunity - health · 2020 · DOI
This study looked at immune system markers in the blood of people with ME/CFS and fibromyalgia compared to healthy people. Researchers found that one immune marker called MCP-1 was higher in patients, while many other immune markers were actually lower than in healthy controls. This suggests the immune system may work differently in these conditions, though the exact meaning of these differences is still unclear.
Understanding immune dysregulation in ME/CFS is crucial for developing targeted therapies. This study provides evidence that ME/CFS involves a distinctive immune profile characterized by selective elevation of MCP-1 alongside broader suppression of other immune markers, which may guide future immunological interventions and biomarker research.
This study does not prove that these immune markers cause ME/CFS or fibromyalgia—only that they are associated with the conditions at a single time point. The cross-sectional design cannot establish whether the immune changes precede illness onset, are consequences of chronic illness, or play a causal role. The study also does not explain what these immune changes mean functionally or whether they persist over time.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →